DK3539545T3 - Krystallinsk form af gnrh-receptorantagonist og fremgangsmåde til fremstilling deraf - Google Patents
Krystallinsk form af gnrh-receptorantagonist og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK3539545T3 DK3539545T3 DK17869463.4T DK17869463T DK3539545T3 DK 3539545 T3 DK3539545 T3 DK 3539545T3 DK 17869463 T DK17869463 T DK 17869463T DK 3539545 T3 DK3539545 T3 DK 3539545T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparing
- receptor antagonist
- gnrh receptor
- crystallic
- crystallic form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610999743 | 2016-11-14 | ||
| PCT/CN2017/110685 WO2018086608A1 (zh) | 2016-11-14 | 2017-11-13 | 一种GnRH受体拮抗剂的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3539545T3 true DK3539545T3 (da) | 2021-09-27 |
Family
ID=62109467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17869463.4T DK3539545T3 (da) | 2016-11-14 | 2017-11-13 | Krystallinsk form af gnrh-receptorantagonist og fremgangsmåde til fremstilling deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10787451B2 (da) |
| EP (1) | EP3539545B1 (da) |
| JP (1) | JP2019535712A (da) |
| KR (1) | KR102516017B1 (da) |
| CN (1) | CN108778282B (da) |
| AU (1) | AU2017357332B2 (da) |
| BR (1) | BR112019009455A2 (da) |
| CA (1) | CA3040026A1 (da) |
| DK (1) | DK3539545T3 (da) |
| ES (1) | ES2887018T3 (da) |
| HR (1) | HRP20211379T1 (da) |
| HU (1) | HUE055891T2 (da) |
| PL (1) | PL3539545T3 (da) |
| PT (1) | PT3539545T (da) |
| TW (1) | TWI774704B (da) |
| WO (1) | WO2018086608A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113993858B (zh) * | 2019-04-30 | 2024-05-28 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途 |
| TW202302592A (zh) * | 2021-04-02 | 2023-01-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | GnRH受體拮抗劑的結晶形式及其製備方法 |
| TW202315622A (zh) * | 2021-08-30 | 2023-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種GnRH受體拮抗劑的結晶工藝 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006220559A1 (en) | 2005-03-07 | 2006-09-14 | Wyeth | Quinoxaline dihydrohalide dihydrates and synthetic methods therefor |
| EP2329823A4 (en) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED |
| TW201130854A (en) | 2009-12-22 | 2011-09-16 | Bayer Schering Pharma Ag | Pyridinone derivatives and pharmaceutical compositions thereof |
| WO2012175514A1 (en) | 2011-06-21 | 2012-12-27 | Bayer Intellectual Property Gmbh | Pyridinone derivatives and pharmaceutical compositions thereof |
| SI2900675T1 (sl) * | 2012-09-28 | 2019-06-28 | Takeda Pharmaceutical Company Limited | Postopek za pridobivanje tienopirimidin derivata |
| JP6412563B2 (ja) * | 2013-10-30 | 2018-10-24 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ピラゾロピリミドンまたはピロロトリアゾン誘導体、その製造方法、およびそれらの医薬適用 |
| CN104788435A (zh) * | 2014-01-16 | 2015-07-22 | 江苏恒瑞医药股份有限公司 | 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐的i型结晶 |
-
2017
- 2017-11-13 KR KR1020197015658A patent/KR102516017B1/ko active IP Right Grant
- 2017-11-13 PL PL17869463T patent/PL3539545T3/pl unknown
- 2017-11-13 CA CA3040026A patent/CA3040026A1/en active Pending
- 2017-11-13 US US16/348,932 patent/US10787451B2/en not_active Expired - Fee Related
- 2017-11-13 CN CN201780017902.8A patent/CN108778282B/zh active Active
- 2017-11-13 BR BR112019009455A patent/BR112019009455A2/pt active Search and Examination
- 2017-11-13 JP JP2019525785A patent/JP2019535712A/ja active Pending
- 2017-11-13 AU AU2017357332A patent/AU2017357332B2/en not_active Ceased
- 2017-11-13 HU HUE17869463A patent/HUE055891T2/hu unknown
- 2017-11-13 EP EP17869463.4A patent/EP3539545B1/en active Active
- 2017-11-13 PT PT178694634T patent/PT3539545T/pt unknown
- 2017-11-13 DK DK17869463.4T patent/DK3539545T3/da active
- 2017-11-13 TW TW106139177A patent/TWI774704B/zh not_active IP Right Cessation
- 2017-11-13 ES ES17869463T patent/ES2887018T3/es active Active
- 2017-11-13 WO PCT/CN2017/110685 patent/WO2018086608A1/zh active Application Filing
-
2021
- 2021-08-30 HR HRP20211379TT patent/HRP20211379T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20211379T1 (hr) | 2021-12-10 |
| CN108778282A (zh) | 2018-11-09 |
| AU2017357332B2 (en) | 2021-10-28 |
| CN108778282B (zh) | 2021-07-27 |
| WO2018086608A1 (zh) | 2018-05-17 |
| EP3539545A1 (en) | 2019-09-18 |
| EP3539545A4 (en) | 2020-07-01 |
| KR102516017B1 (ko) | 2023-03-30 |
| US10787451B2 (en) | 2020-09-29 |
| AU2017357332A1 (en) | 2019-05-09 |
| TW201817734A (zh) | 2018-05-16 |
| BR112019009455A2 (pt) | 2019-07-30 |
| PL3539545T3 (pl) | 2022-01-10 |
| KR20190080915A (ko) | 2019-07-08 |
| US20190276455A1 (en) | 2019-09-12 |
| TWI774704B (zh) | 2022-08-21 |
| JP2019535712A (ja) | 2019-12-12 |
| HUE055891T2 (hu) | 2022-01-28 |
| PT3539545T (pt) | 2021-09-06 |
| CA3040026A1 (en) | 2018-05-17 |
| EP3539545B1 (en) | 2021-08-11 |
| ES2887018T3 (es) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3660004T3 (da) | Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor | |
| DK3298043T3 (da) | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse | |
| DK3227310T3 (da) | Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3294865T3 (da) | Fremgangsmåder til fremstilling af epimeraser og benzylisoquinolinalkaloider | |
| DK3473621T3 (da) | Fremgangsmåde til fremstilling af diphenylmethan-derivat | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3280710T3 (da) | Fremgangsmåde til fremstilling af androgenreceptorantagonister og mellemprodukter deraf | |
| DK3349772T3 (da) | Fremgangsmåde til fremstilling af urteekstrakter | |
| DK3180290T3 (da) | Fremgangsmåde til ekstraktion og separation af sjældne jordarter | |
| DK3280839T3 (da) | Indretning til fremføring og spredning af stofstykker | |
| DK3389636T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler | |
| DK3356386T3 (da) | Fremgangsmåde til behandling af melanocortin-4 receptorbane-associerede lidelser | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3487443T3 (da) | Fremgangsmåde til opmåling af en implantat-implantat-situation | |
| DK3441381T3 (da) | Fremgangsmåde til fremstilling af methanol og indretning til fremstilling af methanol | |
| DK3574135T3 (da) | Fremgangsmåde og formulering til fremstilling af ligninfibre | |
| DK3380456T3 (da) | Kompleks af angiotensin receptor antagonist og neutral endopeptidase inhibitor | |
| DK3218351T3 (da) | Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377 | |
| DK3472338T3 (da) | Midler og fremgangsmåder til at modifikation af flere alleler | |
| DK3630772T3 (da) | Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere | |
| DK3495352T3 (da) | Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf | |
| DK3419480T3 (da) | System og fremgangsmåde til automatiseret fremstilling af betonstrukturelement | |
| DK3072560T3 (da) | Trampolinsystemer og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3297631T3 (da) | NK-1/NK-3-receptorantagonist til behandling af hedeture |